Madrigal Pharmaceuticals (MDGL) Earnings Date & Reports

Key Takeaways

• Madrigal reported third-quarter 2026 net sales of $431.3 million, up 50% year over year, driven entirely by its lead therapy Rezdiffra.
• The company delivered net income of $55.4 million, or $1.90 per basic share ($1.83 diluted), marking its first-ever profitable quarter versus a net loss of $114.2 million a year earlier.
• Year-to-date Rezdiffra net sales crossed $1 billion, reaching blockbuster status less than three years after launch, with more than 55,850 patients actively on therapy at quarter end.
• Operating cash flow was positive for a second consecutive quarter, and cash and marketable securities totaled $961.8 million.
• Management narrowed its F4c (compensated cirrhosis) outcomes readout to late 2027 and unveiled a second Phase 3 trial, MAESTRO-CSPH, expected to begin in the first half of 2027.
• For more information about the company's Major News, Today's Price Move, Price Targets, and Forecast, explore the additional pages available for MDGL.
• Explore Trending AI Robots to discover AI-driven trading strategies and market signals.

Earnings Context and Why It Matters

Madrigal Pharmaceuticals is a commercial-stage biopharmaceutical company focused on metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need. Its lead drug, Rezdiffra (resmetirom), was the first therapy approved in both the U.S. and Europe for MASH with moderate to advanced fibrosis, and its commercial ramp has been one of the strongest recent specialty launches in biotech. This quarter matters because it represents a pivotal transition: after years of funding operations through equity financing, Madrigal has now reported its first period of profitability. The results also offer a direct read on Rezdiffra's prescriber adoption, patient growth, and market-access execution, all of which anchor the company's long-term investment case.

Reported Results

For the third quarter ended September 30, 2026, Madrigal reported net sales of $431.3 million, a 50% increase from $287.3 million in the prior-year period. Year-to-date net sales reached $1.1 billion, pushing Rezdiffra past blockbuster status. Net income was $55.4 million, or $1.90 per basic share ($1.83 per diluted share), compared with a net loss of $114.2 million, or $4.01 per share, a year earlier. The result beat expectations that had called for a loss and marked the company's first profitable quarter.

Operating expenses declined to $375.3 million from $401.2 million, largely reflecting a prior-year one-time $117.3 million upfront business development charge in research and development (R&D). R&D expense fell to $71.8 million from $174 million, while selling, general, and administrative (SG&A) expense rose to $265.7 million from $209.1 million as the company expanded its commercial footprint. Management now expects 2026 gross-to-net in the low end of its mid-to-high 30s range, with R&D guided nominally lower than 2025.

AI Screener

Tickeron's AI Screener is an AI-powered stock and exchange-traded fund (ETF) discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking the biotech sector or monitoring names like MDGL, the AI Screener offers a structured way to surface relevant candidates quickly.

Market Reaction and Investor Sentiment

Investor sentiment heading into the report had centered on whether Madrigal could sustain Rezdiffra's rapid launch trajectory and convert rising revenue into profitability. The company delivered a positive earnings surprise relative to expectations for a loss, reinforced by a 50% year-over-year sales increase and a near doubling of active patients to more than 55,850. That said, the stock has faced debate over decelerating year-over-year growth rates and 2027 pricing pressure tied to Medicare Part D contracts. Management also cautioned that the company may move in and out of profitability near term due to investment timing and typical first-quarter seasonality, giving investors reason to weigh near-term volatility against longer-term commercial momentum.

Forward Outlook and Key Factors to Monitor

Following this milestone quarter, investors should watch several factors tied to Rezdiffra's commercial execution. First is patient growth and prescriber depth, since Madrigal's revenue depends on continued new patient starts and adherence within its approved F2-F3 (moderate-to-advanced fibrosis) population. Management described the U.S. F2-F3 MASH market as accelerating, on track to grow more than 30% in 2026, but gross-to-net pressure is expected to rise toward the high end of the range in 2027 as Medicare Part D contracts take effect.

Second is expense discipline. SG&A is guided higher in the fourth quarter, and the newly announced MAESTRO-CSPH trial will add multi-year spending. Because the company may dip in and out of profitability, the path of operating cash flow and the $961.8 million cash position will remain key signals of financial flexibility.

Finally, the pipeline is a longer-term driver. Madrigal now anticipates the MAESTRO-NASH OUTCOMES readout in late 2027 and plans to initiate the MAESTRO-CSPH study, enriched for clinically significant portal hypertension (CSPH), in the first half of 2027. Management has also outlined more than ten combination programs, with three Phase 2 trials planned for 2027, positioning the company to extend its leadership in MASH.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations